Network pharmacology and transcriptomics analyses were first conducted to identify potential bioactive compounds in SGD targeting LDD and their molecular targets, leading to the identification of quercetin as a compound stabilizing hypoxia-inducible factor 1-alpha (HIF1A) protein. The gene discussed is HIF1A; the disease is Lhermitte-Duclos disease.